Lipika Goyal, MD
Medical Oncology · Stanford, CANPI 1720287055
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $124,466 of the $166,007 with a category attached, or 75.0%. 21 manufacturers reported payments, led by Taiho Oncology, Inc. at 29.9% of the total. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $1238.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Taiho Oncology, Inc.$50K
- AstraZeneca$22K
- Astrazeneca UK Limited$13K
- Sirtex Medical Inc$13K
- Exelixis Inc.$11K
- Incyte Corporation$10K
- plus $47K from 15 others
Across 435 payments — averaging $12,120 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1M
- Taiho Oncology, Inc.$905K
- Genentech, Inc.$834K
- Eli Lilly$624K
- Incyte Corporation$546K
- Merck$458K
- plus $878K from 11 others
What the payments were for
- Consulting fees$124,46675%
- Speaking & faculty fees$30,06318%
- Travel & lodging$8,2575%
- Food & beverage$3,2212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Taiho Oncology, Inc. | 16 | $49,589 |
| AstraZeneca | 17 | $21,638 |
| Astrazeneca UK Limited | 12 | $13,314 |
| Sirtex Medical Inc | 8 | $13,262 |
| Exelixis Inc. | 18 | $11,185 |
| Incyte Corporation | 18 | $9,697 |
| Jazz Pharmaceuticals Inc. | 3 | $8,976 |
| Servier Pharmaceuticals LLC | 7 | $7,471 |
| Boehringer Ingelheim International GmbH | 5 | $6,961 |
| Merck | 6 | $6,629 |
| Agios Pharmaceuticals, Inc. | 8 | $5,511 |
| Genentech, Inc. | 4 | $4,575 |
| Guerbet LLC | 1 | $2,000 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,910 |
| Genentech USA, Inc. | 4 | $1,247 |
| Blueprint Medicines Corporation | 1 | $1,008 |
| AbbVie | 1 | $675 |
| Array Biopharma Inc | 1 | $139 |
| Trisalus Life Sciences, Inc. | 1 | $123 |
| Boehringer Ingelheim | 1 | $62 |
| Eisai Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$166,007 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.